PROVIDING PATIENTS GLOBAL ACCESS TO GAME-CHANGING RADIOPHARMACEUTICALS

Statement Attributable to:
Frank Scholz, Ph.D., President and COO, NorthStar Medical Radioisotopes

NorthStar Medical Radioisotopes, located in Beloit, Wisconsin, (“NorthStar”) recognizes the urgent medical need for technetium-99m (Tc-99m) to ensure patients have access to critical diagnostic imaging tests. Tc-99m is generated from molybdenum-99 (Mo-99) and used in over 40,000 patient studies per day in the United States. The overseas Mo-99 supply chain has historically been fragile and remains so today. Currently, several overseas reactors that produce Mo-99 are offline. As a result, the U.S. Food and Drug Administration (FDA) has placed Technetium Tc 99m Sodium Pertechnetate generators on the Drug Shortages List, recognizing its importance as a medically necessary product.